BR0316296A - Compostos lapacone e seus métodos de uso - Google Patents

Compostos lapacone e seus métodos de uso

Info

Publication number
BR0316296A
BR0316296A BR0316296-6A BR0316296A BR0316296A BR 0316296 A BR0316296 A BR 0316296A BR 0316296 A BR0316296 A BR 0316296A BR 0316296 A BR0316296 A BR 0316296A
Authority
BR
Brazil
Prior art keywords
compounds
lapacone
methods
treatment
psoriasis
Prior art date
Application number
BR0316296-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhiwei Jiang
Dasharatha Reddy
Samuel K Ackerman
Xiangao Sun
Youzhi Li
Chiang Li
June Salvesen
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/022631 external-priority patent/WO2004007531A2/en
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BR0316296A publication Critical patent/BR0316296A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0316296-6A 2002-11-18 2003-11-18 Compostos lapacone e seus métodos de uso BR0316296A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
PCT/US2003/022631 WO2004007531A2 (en) 2002-07-17 2003-07-17 Activated checkpoint therapy and methods of use thereof
US10/622,854 US20040209942A1 (en) 2002-07-17 2003-07-17 Activated checkpoint therapy and methods of use thereof
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BR0316296A true BR0316296A (pt) 2005-12-13

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316296-6A BR0316296A (pt) 2002-11-18 2003-11-18 Compostos lapacone e seus métodos de uso

Country Status (12)

Country Link
US (1) US20040266857A1 (enExample)
EP (1) EP1567515A4 (enExample)
JP (1) JP2006508147A (enExample)
CN (1) CN1729183A (enExample)
AR (1) AR056613A1 (enExample)
AU (1) AU2003295738A1 (enExample)
BR (1) BR0316296A (enExample)
CA (1) CA2506340A1 (enExample)
EA (1) EA200500849A1 (enExample)
MX (1) MXPA05005314A (enExample)
TW (1) TW200510367A (enExample)
WO (1) WO2004045557A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
US7649013B2 (en) 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
EP2033639A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of colon cancer
JP2007523190A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 肺癌の治療のためのβ−ラパコンの使用
EP2033638A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of pancreatic cancer
EP1722776A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2005082357A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
JP2009538298A (ja) * 2006-05-26 2009-11-05 アークル インコーポレイテッド 新規のラパコン化合物およびその使用方法
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2532656T3 (es) 2007-04-30 2015-03-30 Arqule, Inc. Compuestos de hidroxi sulfonato de quinona y sus usos
US8067459B2 (en) 2007-10-16 2011-11-29 Arqule, Inc. Lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
RU2016140440A (ru) * 2010-06-01 2018-12-14 Белле-Эйр Фрейгренсиз, Инк. Способ и продукт для борьбы с запахом изо рта
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof

Also Published As

Publication number Publication date
AR056613A1 (es) 2007-10-17
EP1567515A4 (en) 2008-04-23
WO2004045557A2 (en) 2004-06-03
US20040266857A1 (en) 2004-12-30
JP2006508147A (ja) 2006-03-09
TW200510367A (en) 2005-03-16
AU2003295738A1 (en) 2004-06-15
WO2004045557A3 (en) 2004-08-12
CN1729183A (zh) 2006-02-01
CA2506340A1 (en) 2004-06-03
EA200500849A1 (ru) 2006-02-24
EP1567515A2 (en) 2005-08-31
MXPA05005314A (es) 2005-10-19

Similar Documents

Publication Publication Date Title
BR0316296A (pt) Compostos lapacone e seus métodos de uso
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
UY27807A1 (es) Nuevos derivados de piridazin-3(2h)-ona
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
DK0842934T3 (da) 5-HT1F agonister
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
UY27760A1 (es) Nuevos derivados de pirrolidinio.
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
YU21401A (sh) Tetrahidropiridoetri
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR024138A1 (es) Inhibidores de la proliferacion celular
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
SE9802208D0 (sv) Novel compounds
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
PT916670E (pt) Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]